This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $63.83, marking a -0.79% move from the previous day.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) Stock Moves -0.03%: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $61.95, marking a -0.03% move from the previous day.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $66.24 in the latest trading session, marking a -0.47% move from the prior day.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
by Zacks Equity Research
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic (HOLX) Stock Moves -0.35%: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $65, moving -0.35% from the previous trading session.
Hologic (HOLX) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $62.71 in the latest trading session, marking a -0.29% move from the prior day.
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $67.99, moving -0.04% from the previous trading session.
Is Most-Watched Stock Hologic, Inc. (HOLX) Worth Betting on Now?
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why Investors Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) better-than-expected results and expanded Panther installed base.
Hologic (HOLX) Just Reclaimed the 200-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's How Much a $1000 Investment in Hologic Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Thermo Fisher (TMO) Debuts Assay for Research on HIV Strains
by Zacks Equity Research
Thermo Fisher's (TMO) novel Applied Biosystems HIV-1 Genotyping Kit will aid in the global efforts to monitor the evolution of HIV.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic (HOLX) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Hologic (HOLX) reports better-than-expected results in the fiscal third quarter with robust sales performance in the GYN Surgical business.
Hologic (HOLX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 37.68% and 11.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Earnings Due on Jul 27: BSX, HOLX & ALGN
by Urmimala Biswas
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how BSX, HOLX and ALGN fare this time.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $70.11, moving -0.54% from the previous trading session.
Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings
by Zacks Equity Research
Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) Q3 results will likely gain from the continued uptake of its Panther instruments and an ongoing rebound in elective procedures.
Hologic (HOLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $71.42, marking a +0.06% move from the previous day.